Cited by 173Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and ManagementImmunotherapy and Immune Responses

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Complete response of metastatic melanoma in a patient with Crohn’s disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies

Open access

Frohne, Christopher C., Llano, Ernesto M., Perkovic, Ashley, Cohen, Russell D., Luke, Jason J.·2019·Journal for ImmunoTherapy of Cancer

DOI 10.1186/s40425-018-0484-xPMC PMC6322234

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Immune checkpoint inhibitors (ICPIs) are increasingly being used in the treatment of a variety of malignancies. The original studies that demonstrated the efficacy of ICPIs excluded patients actively being treated for autoimmune conditions, and there is only limited evidence that these treatments are safe and effective in this population of patients. CASE PRESENTATION: We present a case of a man with Crohn's disease actively requiring immunosuppressive therapy who subsequently received pembrolizumab for metastatic melanoma. He had no further progression of metastatic disease and had resolution of his pulmonary nodule while he experienced no Crohn's disease flares or immune related adverse events. We surveyed the existing literature for studies examining the use of ICPIs in patients with autoimmune disorders and reviewed the unique mechanism of action of the α4β7 inhibitor, vedolizumab. CONCLUSION: Patients with autoimmune conditions should be considered candidates for immune checkpoint inhibition even in the setting of active immunosuppressive therapy. The mechanism of action of immunosuppressive therapy should be considered with the most targeted form of treatment being used when possible. Further prospective studies investigating immunotherapy in patients with autoimmune conditions are warranted.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1186/s40425-018-0484-x

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Fig. 1 Comparison of Terminal Ileum from Colonoscopy in 2012 to Colonoscopy in 2017, (Left) inflammation of the terminal ileum on colonoscopy in 2012 while on azathioprine and oral/rectal mesalamine. (Right) normal mucosa of the terminal ileum on colonoscopy in May 2017 while on vedolizumabCC BY · PubMed Central

Fig. 2 Resolution of Metastatic Pulmonary Nodule after Treatment with Pembrolizumab, (Left) CT chest from 9/22/2017 revealing RML nodule 1.2 × 1.0 cm in size. (Right) CT chest from 12/14/2017 demonstrating interval resolution of RML nodule after 4 cycles of pembrolizumabCC BY · PubMed Central

Fig. 3 Comparison of Sacral Metastasis Showing No Progression after Treatment with Pembrolizumab and SBRT, (Left) CT abdomen/pelvis sagittal view from 9/22/2017 revealing metastasis in the S1 vertebral body extending posteriorly into the spinal canal. (Right) CT abdomen/pelvis axial view from 12/14/2017 showing unchanged size of sacral metastasisCC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P. J., Hanauer, S. B., Colombel, J., Sands, B. E., Lukáš, M., Fedorak, R. N., Lee, S., Bressler, B. L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,716
Using immunotherapy to boost the abscopal effect
Ngwa, W., Irabor, O. C., Schoenfeld, J. D., Hesser, J., Demaria, S., & Formenti, S. C. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.6 · Cited by 1,260
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A. A., Routier, É., Lambotte, O., Ladurie, F. L. R., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,100
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
Menzies, A. M., Johnson, D. B., Ramanujam, S., Atkinson, V. G., Wong, A. N. M., Park, J. J., McQuade, J. L., Shoushtari, A. N., Tsai, K. K., Eroglu, Z., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw443 · Cited by 817

Show all 20 references

Sorted by citations

Items 101–173 of 173

Melanoma immunotherapy enabled by M2 macrophage targeted immunomodulatory cowpea mosaic virus
Zhao, Z., Chung, Y. H., & Steinmetz, N. F. (2024) · Materials Advances · doi:10.1039/d3ma00820g · Cited by 9
The current use of nanotechnology in the fight against antimicrobial resistance: promising approaches to global health challenge
Mmbando, G. S., Ally, O., & Kitimu, S. R. (2025) · Journal of Nanoparticle Research · doi:10.1007/s11051-025-06290-6 · Cited by 9
The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles
Molvi, Z., Klatt, M. G., Dao, T., Urraca, J., Scheinberg, D. A., & O’Reilly, R. J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006889 · Cited by 9
Safety of Immune Checkpoint Blockade in Patients with Cancer and Preexisting Autoimmune Diseases and/or Chronic Inflammatory Disorders
Shah, M., Jizzini, M., Majzoub, I. E., Qdaisat, A. Z., Reyes‐Gibby, C. C., & Yeung, S. J. (2019) · Journal of Immunotherapy and Precision Oncology · doi:10.4103/jipo.jipo_11_19 · Cited by 9
Liposomes for Advanced Drug Delivery
Verma, A., Tiwari, A., Panda, P. K., Saraf, S., Jain, A., Raikwar, S., Bidla, P. D., & Jain, S. (2020) · Advances in material research and technology · doi:10.1007/978-3-030-46923-8_12 · Cited by 9
Citronellal suppress the activity of ornithine decarboxylase in hypopharyngeal carcinoma cells
Fatima, K., & Luqman, S. (2021) · South African Journal of Botany · doi:10.1016/j.sajb.2021.07.043 · Cited by 9
The role of tumor types in immune-related adverse events
Xu, Q., Hu, J., Wang, Y., & Wang, Z. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03798-6 · Cited by 9
Experiences of cancer immunotherapy with immune checkpoint inhibitors (ExCIm)—insights of people affected by cancer and healthcare professionals: a qualitative study protocol
Jennings, S., Anstey, S., Bower, J., Brewster, A. E., Buckman, J., Fenlon, D., Fitzsimmons, D. F., & Watts, T. E. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-043750 · Cited by 8
Durable Metastatic Melanoma Remission Following Pembrolizumab and Radiotherapy: A Case Report of Prophylactic Immunosuppression in a Patient with Myasthenia Gravis and Immune-Mediated Colitis
Moradi, L. A., Clark, C. A., Schneider, C. S., Deshane, A. S., & Dobelbower, M. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.788499 · Cited by 8
A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy
Bigelow, E., Saria, S., Piening, B., Curti, B. D., Dowdell, A. K., Weerasinghe, R. K., Bifulco, C. B., Urba, W. J., Finkelstein, N., Fertig, E. J., et al. (2022) · Cancer Informatics · doi:10.1177/11769351221136081 · Cited by 7
Construction and Application of a PD-L1-Targeted Multimodal Diagnostic and Dual-Functional Theranostics Nanoprobe
He, C., Guo, Y., Zhou, N., Wang, Z., Liu, T., Xu, X., Wang, F., Zhu, H., Yang, Z., Yang, X., et al. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s461701 · Cited by 7
Revolutionising cancer intervention: the repercussions of CAR-T cell therapy on modern oncology practices
Kamli, H. M., & Khan, N. U. (2025) · Medical Oncology · doi:10.1007/s12032-025-02783-5 · Cited by 7
The prognostic role of early tumor shrinkage in patients with hepatocellular carcinoma undergoing immunotherapy
Müller, L., Gairing, S. J., Kloeckner, R., Foerster, F., Schleicher, E. M., Weinmann, A., Mittler, J., Stoehr, F., Halfmann, M. C., Düber, C., et al. (2022) · Cancer Imaging · doi:10.1186/s40644-022-00487-x · Cited by 7
Collision Induced Unfolding Enables the Quantitation of Isomass Biotherapeutics in Complex Biological Matrices
Juliano, B. R., & Ruotolo, B. T. (2023) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.3c00234 · Cited by 8
Wild-type KRAS activation drives evasion of interferon-mediated immunity and resistance to immunotherapy in hepatocellular carcinoma
Lei, M. M. L., Leung, C. O. N., Leung, R. W. H., Wu, X., Chung, K. P. S., Gu, C. Y. J., Chan, M. S. M., Chau, W. K., Mu, Q. H., Ng, K. Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64860-7 · Cited by 6
Telomere length sensitive regulation of interleukin receptor 1 type 1 (IL1R1) by the shelterin protein TRF2 modulates immune signalling in the tumour microenvironment
Mukherjee, A. K., Dutta, S., Singh, A., Sharma, S., Roy, S. S., Sengupta, A., Chatterjee, M., Vinayagamurthy, S., Bagri, S., Khanna, D., et al. (2024) · eLife · doi:10.1101/2021.12.07.471419 · Cited by 7
The role of pyroptosis-related lncRNA risk signature in ovarian cancer prognosis and immune system
Wu, Y., Liang, L., Li, Q., Shu, L., Wang, P., & Huang, S. (2023) · Discover Oncology · doi:10.1007/s12672-023-00767-3 · Cited by 6
Immune checkpoint inhibitors: current status
dos Reis, A. F. P., Hennig, I. M., & Wilcock, A. (2021) · BMJ Supportive & Palliative Care · doi:10.1136/bmjspcare-2021-002954 · Cited by 6
Three-Dimensional Bioconjugated Liquid-Like Solid (LLS) Enhance Characterization of Solid Tumor - Chimeric Antigen Receptor T cell interactionsPreprint
Nguyen, D., Liu, R., Ogando‐Rivas, E., Pepe, A., Pedro, D. I., Qdasait, S., Nguyen, N. T. Y., Lavrador, J. M., Golde, G. R., Smolchek, R. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.17.529033 · Cited by 5
Mapping the immunological landscape and emerging immunotherapeutic strategies in cervical cancer: a comprehensive review
Zhang, X., Nie, W., Shao, W., & Guo, Q. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1620501 · Cited by 4
Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Solid Tumors
Esmaeilzadeh, A., Jafari, D., Elahi, R., Bazargan, M., Rafie, M. Z., & Mansourabadi, A. H. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2023_156 · Cited by 4
The Influence of Macrophages within the Tumor Microenvironment on Ovarian Cancer Growth and Response to TherapiesPreprint
Nikeghbal, P., Burke, D., Armijo, D., Aldarondo-Quiñones, S., Lidke, D. S., & Steinkamp, M. P. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.29.635532 · Cited by 4
Implementation of multiomic mass spectrometry approaches for the evaluation of human health following environmental exposure
Ferreira, C. R., Gomes, P. C. F. D. L., Robison‡, K. M., Cooper, B. R., & Shannahan, J. H. (2024) · Molecular Omics · doi:10.1039/d3mo00214d · Cited by 4
Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer
Hummelink, K., van der Noort, V., Muller, M., Schouten, R. D., van den Heuvel, M. M., Thommen, D. S., Smit, E. F., Meijer, G. A., & Monkhorst, K. (2024) · PLoS ONE · doi:10.1371/journal.pone.0293707 · Cited by 3
Clinical perspective and treatment of immune-related colitis after cancer immunotherapy
Braun, L. M., Lu, Y., & Zeiser, R. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.07.005 · Cited by 6
Immunosuppressive therapy management in cancer patients with autoimmune diseases treated with immune checkpoint inhibitors: A case series and systematic literature review
Wuyts, S. C. M., Cappelle, C. A. H., Verhaert, M., Bravenboer, B., & Aspeslagh, S. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231167824 · Cited by 3
Investigating the Use of Novel Blood Processing Methods to Boost the Identification of Biomarkers for Non-Small Cell Lung Cancer: A Proof of Concept
McMahon, R., Lucas, N., Hill, C. J., Pascovici, D., Herbert, B. R., & Karsten, E. (2024) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00829 · Cited by 3
Obesity, Cancer and the Immune System: Cross Talks and Complex Interplay
Kamel, H. F. M., Al-Amodi, H. S. A. B., & Abdelsattar, S. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_105-1 · Cited by 3
Targeted LNPs deliver mRNA encoding IL-15 superagonists to balance efficacy and toxicity in cancer therapyPreprint
Yu, J., Li, Q., Luo, S., Wang, X., Cheng, Q., & Hu, R. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.11.575299 · Cited by 3
Advances in mechanistic investigation and treatment of steroid-refractory ICI-induced liver injury
Hu, H., Shen, X., & Chen, J. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01721-z · Cited by 2
Intravenous administration of CpG7909 lipoplex enhances anti-PD1 immunotherapy by modulating the tumor microenvironment and inducing durable tumor regression
Tu, C.-M., Lin, M.-H., Liu, C.-P., Chen, S.-T., Liu, C.-M., She, M., Wang, Y., Wang, H.-C., Chang, Y., Chang, L.-W., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-29622-x · Cited by 2
Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab
Graser, C. J., McDonald, T. O., Catalano, P. J., Sonpavde, G., & Michor, F. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011740 · Cited by 2
A Head Start: CAR-T Cell Therapy for Primary Malignant Brain Tumors
Tschernia, N. P., & Khagi, S. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00772-6 · Cited by 2
Metastatic Melanoma Treatment in Special Populations
Miceli, M., Boatwright, C., & Mehnert, J. M. (2024) · The Cancer Journal · doi:10.1097/ppo.0000000000000701 · Cited by 1
CRISPR-Cas9 in cancer therapy: Revolutionizing oncology through targeted gene editing
Deng, H. (2024) · E3S Web of Conferences · doi:10.1051/e3sconf/202455305046 · Cited by 1
Identifying the therapeutic potential of niclosamide in overcoming IFN-gamma dependent cancer immune evasion in the tumor microenvironment
Zhang, Y., Peng, S., Akhbariyoon, H., Kim, S., Lai, E., & Cai, E. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1761715 · Cited by 1
Research Strategies for Low-Survival Cancers
Conway, C., Collins, D. M., McCann, A. H., & Dean, K. A. (2021) · Cancers · doi:10.3390/cancers13030528 · Cited by 1
High-throughput proliferation and activation of NK-92MI cell spheroids via a homemade one-step closed bioreactor in pseudostatic cultures for immunocellular therapy
Lin, J., Kuan, C., Chang, C., Chen, Z., Kuo, W., Lin, J., Lin, Y.-Y., Yang, I., & Lin, F. (2024) · Journal of Biological Engineering · doi:10.1186/s13036-024-00461-0 · Cited by 1
CMTM6 status predicts survival in head and neck squamous cell carcinoma and correlates with PD-L1 expression
Becker, A., Wieder, N. W., Zonnur, S., Zimpfer, A., Krause, M., Schneider, B., Strüder, D., Burmeister, A.-S., Erbersdobler, A., Junghanss, C., et al. (2024) · Discover Oncology · doi:10.1007/s12672-024-01554-4 · Cited by 1
Interdisciplinary Approach in Head and Neck Cancers
Sabahi, M., Hanaei, S., & Rezaei, N. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_67 · Cited by 1
Human cytokine-induced memory-like NK cells preserve increased glycolysis but the glycolytic-dependence of their effector functions differ between stimuliPreprint
Terrén, I., Orrantia, A., Mosteiro, A., Vitallé, J., Zenarruzabeitia, O., & Borrego, F. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.20.258731 · Cited by 1
Clonally-Expanded, Thyrotoxic Autoimmune Mediator CD8 + T cells Driven by IL21 Contribute to Checkpoint Inhibitor ThyroiditisPreprint
Lechner, M. G., Zhou, Z., Hoang, A. T., Huang, N., Ortega, J., Scott, L. N., Chen, H.-C., Patel, A. Y., Tafti, R. Y., Kim, K., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.18.517398 · Cited by 1
Interruption of the Intratumor CD8:Treg Crosstalk Improves the Efficacy of PD-1 ImmunotherapyPreprint
Geels, S. N., Moshensky, A., Sousa, R. S., Walker, B. L., Singh, R., Gutierrez, G., Hwang, M., Mempel, T. R., Nie, Q. H., Othy, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.15.540889 · Cited by 1
The anti-virus T cell response dominates the anti-cancer response in oncolytic virus therapyPreprint
O’Melia, M. J., Sierra-Davidson, K., Robert, M. A., Menzel, L., Liu, L., Lei, P., Munn, L. L., Padera, T. P., & Cohen, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.22.677905 · Cited by 1
Gleichzeitig Checkpointhemmer und Immunsuppressoren?
Müller, T. M. (2019) · Der Deutsche Dermatologe · doi:10.1007/s15011-019-2348-1
An innovative approach for HLA typing, molecular tumor testing and the validation of tumor exclusive antigensPreprint
Ghosh, M., Bichmann, L., Scheid, J., GÜLER, G., Schuster, H., Marco, M. D., Marcu, A., Beyer, M., Nelde, A., Freudenmann, L. K., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.05.136754
Tumorimpfstoffe
Roerden, M., & Walz, J. S. (2021) · best practice onkologie · doi:10.1007/s11654-021-00356-2
Prognostic and immunotherapeutic significance of tumor- infiltrating M2 macrophages in muscle-invasive bladder cancer
Liu, G., Bolkov, M. A., Shinwari, K., Тузанкина, И. А., & Черешнев, В. А. (2022) · AIP conference proceedings · doi:10.1063/5.0069183
Peripheral monocyte transcriptomics associated with immune checkpoint blockade outcomes in metastatic melanomaPreprint
Cooper, R. A., Taylor, C. A., Watson, R. A., Tong, O., Nassiri, I., Sharma, P. K., Little, M., Ye, W., Koturan, S., Danielli, S., et al. (2024) · medRxiv · doi:10.1101/2024.01.25.24301653
Additional file 5 of EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers
Zhang, Z., Wu, H., Lin, W., Wang, Z., Yang, L.-P., Zeng, Z.-L., & Luo, H. (2021) · Figshare · doi:10.6084/m9.figshare.13685036
Additional file 6 of EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers
Zhang, Z., Wu, H., Lin, W., Wang, Z., Yang, L.-P., Zeng, Z.-L., & Luo, H. (2021) · Figshare · doi:10.6084/m9.figshare.13685039
The incidence of TP53 mutations in patients with chronic lymphocytic leukemia in Iran
Bayati, N., Emtiazi, N., Poopak, B., & Ghiass, M. A. (2024) · Asian Journal of Oncology · doi:10.25259/asjo_33_2023
Research on the Mechanism of Lphn1 Knockout in Inhibiting Colorectal CancerPreprint
Wang, Y. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.07.606975
Immuncheckpointinhibitoren bei Autoimmunerkrankungen
Günther, C., & Steininger, J. (2024) · Im Focus Onkologie · doi:10.1007/s15015-024-3900-8
Paired CRISPR screens to map gene regulation in cis and transPreprint
Xue, X., Gajic, Z. Z., Caragine, C. M., Legut, M., Walker, C. R., Kim, J. Y. S., Wang, X., Yan, R., Wessels, H., Lu, C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.27.625752
Radiation-induced rescue effect on human breast carcinoma cells is regulated by macrophages
Pathikonda, S., Tian, L., Arava, C. M., Cheng, S. H., & Lam, Y. W. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.101936 · Cited by 1
Immuncheckpointinhibitoren bei Autoimmunerkrankungen
Günther, C., & Steininger, J. (2025) · hautnah dermatologie · doi:10.1007/s15012-025-8696-5
Dendritic Cells in Cancer Immunotherapy: Current State and Future Prospects
Dougaheh, S. N. H., Farshbafnadi, M., Yazdanpanah, N., & Rezaei, N. (2025) · Interdisciplinary cancer research · doi:10.1007/16833_2025_503
Circulating Biomarkers for Therapeutic Response to Immune Checkpoint Inhibitor Therapy in Patients with Advanced Lung CancerPreprint
Jain, K., Mehra, D., Yadav, M. C., Aggarwal, S., Chugh, P., Tripathi, G., Ganguly, S., Rana, R., Awasthi, A., Ganguly, N. K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.21.655239
Recurrent Clostridioides Difficile Infection and Colitis Post Immune Checkpoint Inhibitor Therapy
Baerman, E. A., Junek, K., Lavilla, R. C., Wang, X. S., & Wang, Y. (2025) · Springer eBooks · doi:10.1007/978-3-031-83533-9_23
Evaluating the efficacy of neoadjuvant immunotherapy combined with chemotherapy for stage IIIa non-small cell lung cancer
Song, R., Chen, Z., Zheng, T., Huang, J., & Cheng, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-13917-0
Drugging the Medullary Thyroid Cancer Surfaceome with T Cell Engagers Targeting CEA, GFRA4 and DLL3 as Monotherapy and In Combination with Tyrosine Kinase InhibitorsPreprint
Erickson, T. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.05.668474
Body composition and melanoma incidence risk: insights from a longitudinal lung cancer screening cohortPreprint
Yu, T., Kokenberger, G., Wang, J., Meng, X., Davar, D., Storkus, W. J., Kirkwood, J. M., Zarour, H. M., & Pu, J. (2025) · medRxiv · doi:10.1101/2025.10.10.25337772
Additional file 2 of EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers
Zhang, Z., Wu, H.-X., Lin, W.-H., Wang, Z.-X., Yang, L.-P., Zeng, Z.-L., & Luo, H.-Y. (2021) · Figshare · doi:10.6084/m9.figshare.13685024
Additional file 8 of EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers
Zhang, Z., Wu, H.-X., Lin, W.-H., Wang, Z.-X., Yang, L.-P., Zeng, Z.-L., & Luo, H.-Y. (2021) · Figshare · doi:10.6084/m9.figshare.13685045
Additional file 7 of EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers
Zhang, Z., Wu, H.-X., Lin, W.-H., Wang, Z.-X., Yang, L.-P., Zeng, Z.-L., & Luo, H.-Y. (2021) · Figshare · doi:10.6084/m9.figshare.13685042
Additional file 4 of EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers
Zhang, Z., Wu, H.-X., Lin, W.-H., Wang, Z.-X., Yang, L.-P., Zeng, Z.-L., & Luo, H.-Y. (2021) · Figshare · doi:10.6084/m9.figshare.13685033
Additional file 9 of EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers
Zhang, Z., Wu, H.-X., Lin, W.-H., Wang, Z.-X., Yang, L.-P., Zeng, Z.-L., & Luo, H.-Y. (2021) · Figshare · doi:10.6084/m9.figshare.13685048
Additional file 3 of EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers
Zhang, Z., Wu, H.-X., Lin, W.-H., Wang, Z.-X., Yang, L.-P., Zeng, Z.-L., & Luo, H.-Y. (2021) · Figshare · doi:10.6084/m9.figshare.13685030
Additional file 1 of Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer
Hagiwara, Y., Shiroiwa, T., Taira, N., Kawahara, T., Konomura, K., Noto, S., Fukuda, T., & Shimozuma, K. (2020) · Figshare · doi:10.6084/m9.figshare.13185927
Additional file 1 of EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers
Zhang, Z., Wu, H.-X., Lin, W.-H., Wang, Z.-X., Yang, L.-P., Zeng, Z.-L., & Luo, H.-Y. (2021) · Figshare · doi:10.6084/m9.figshare.13685021
Obesity, Cancer and the Immune System: Cross Talks and Complex Interplay
Kamel, H. F. M., Al-Amodi, H. S. A. B., & Abdelsattar, S. (2025) · Springer eBooks · doi:10.1007/978-3-032-00761-2_105
Memory-Like Natural Killer Cells
Sendker, S., Bader, A. C., Hui, V. W., & Romee, R. (2026) · Springer eBooks · doi:10.1007/978-3-662-68816-8_40-1

Authors: Frohne, C. C., Llano, E. M., Perkovic, A., Cohen, R. D., & Luke, J. J.
Affiliations: University of Chicago (US)
Corresponding author: Luke, Jason J.
ORCID: Llano, Ernesto M.
Cohen, Russell D.
Luke, Jason J.
Venue: Journal for ImmunoTherapy of Cancer
Publisher: BMJ
Published: 2019-01-06
Volume: 7
Issue: 1
Pages: 1-1
ISSN: 2051-1426 (ISSN-L)
DOI: 10.1186/s40425-018-0484-x
PMC: PMC6322234
OpenAlex: W2917853396
Cited by: 171
References: 20
Citations by year: 2026: 2 · 2025: 28 · 2024: 25 · 2023: 24 · 2022: 22 · 2021: 42 · 2020: 22 · 2019: 5
FWCI: 9.72
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
Locations: Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, other-oa)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: Department of Defense Career Development Award (W81XWH-17-1-0265)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: metastatic melanoma, Crohn's disease, immune checkpoint inhibitors, pembrolizumab, vedolizumab, anti-PD-1, autoimmune disease, immunosuppressive therapy, immune-related adverse events, pulmonary nodules, complete response
MeSH terms: Antineoplastic Combined Chemotherapy Protocols, Crohn Disease, Humans, Immunosuppression Therapy, Male, Melanoma, Middle Aged, Integrins, Treatment Outcome, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Complete response of metastatic melanoma in a patient with Crohn’s disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks